Why 2018 offers a more 'promising' environment for retail structured products

clock • 2 min read

2017 was a bad year to invest in a new structured product. In an ideal world (where volatility is high and markets have fallen), new structured products can deliver higher potential returns and lower market entry points.

Throughout 2017, volatility for the main equity indices continued the fall that started in the previous year, and most of the same indices slowly increased. AIC reveals Specialist sectors offering highest yield levels By contrast, 2018 has had a much more ‘promising' start from a technical, economic and political perspective. Indices have fallen and volatility is up. These conditions are likely to remain due to concerns about an international trade war, the state of the US economy in a rate-rising environment and the outcome of Brexit negotiations.  The most popular retail struc...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot